Characterisation of a novel ACE2-based therapeutic with enhanced rather than reduced activity against SARS-CoV2 variants
M. Ferrari, L. Mekkaoui, F. T. Ilca, Z. Akbar, R. Bughda, K. Lamb, K. Ward, F. Parekh, R. Karattil, C. Allen, P. Wu, V. Baldan, G. Mattiuzzo, E. M. Bentley, Y. Takeuchi, , S. Onuoha
The paper characterizes a novel ACE2-based therapeutic that effectively neutralizes SARS-CoV-2 variants and demonstrates antibody-like properties and manufacturability.
bioRxiv · Mar 17, 2021Immunology